0
Allergy and Airway |

Tiotropium Delivered via HandiHaler or Respimat: Improvement in Health-Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease

Donald Tashkin; Paul Jones; Thomas Leonard; Dacheng Liu; Norbert Metzdorf; Valentina Zubek; Robert Wise
Author and Funding Information

David Geffen School of Medicine at UCLA, Los Angeles, CA


Chest. 2014;146(4_MeetingAbstracts):49A. doi:10.1378/chest.1994521
Text Size: A A A
Published online

Abstract

SESSION TITLE: COPD Treatment Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM

PURPOSE: To assess the effects of maintenance therapy with tiotropium, a long-acting anticholinergic, on health-related quality of life (HRQoL) in COPD patients using data from 16 clinical trials.

METHODS: Trials included patients with moderate-to-very severe COPD, ≥40 years, smoking history >10 pack-years. Tiotropium was delivered via HandiHaler® (Tio HH; 13 trials) or Respimat® inhaler (Tio R; 3 trials). In the HandiHaler trials, patients were randomized to daily tiotropium 18 μg (13 trials; n=5646), placebo (11 trials; n=4853) and (2 trials) /or (2 trials) active comparator (n=584). In the Respimat trials, patients were randomized to tiotropium 5 μg (Tio R5; 3 trials; n=2219), tiotropium 10 μg (Tio R10; 2 trials, n=619) or placebo (3 trials; n=2318). Treatment duration was 12 weeks to 4 years in the HandiHaler trials and 48 weeks in the Respimat trials. Assessments included: HRQoL, evaluated using the St George’s Respiratory Questionnaire (SGRQ) total score, and the proportion of patients with a minimal clinically important difference (MCID) of ≥4 decrease in SGRQ total score from baseline to trial end.

RESULTS: In the majority of the trials, the mean change in SGRQ total score was statistically significant (P<0.05; tiotropium vs placebo, 12/14 trials; tiotropium vs active comparator, 1/4 trials). Mean change in SGRQ for Tio HH compared with placebo ranged from -1.37 to -6.52 (P<0.05 to <0.0001, 9 trials; P>0.05, 2 trials) and from -1.24 to -4.86 compared with active control (P<0.01, 1 trial; P>0.05, 3 trials). The SGRQ MCID was met in 6 out of 13 HandiHaler trials (5 placebo-controlled, 1 active comparator). In the Respimat trials, the mean change in SGRQ compared with placebo ranged from -2.94 to -3.71(P<0.01, 3 trials) for Tio R5 and -3.45 to -4.24 (P<0.01, 2 trials) for Tio R10. In the HandiHaler trials, responder rate differences for Tio HH vs placebo ranged from 4.4-13.2% at 6 months (9 trials), 7.4-20.4% at 12 months (5 trials) and 8.3-9.0% at 24 months (2 trials). In the Respimat trials responder rate differences at 48 weeks ranged from 7.8-11.8% for Tio R5 (3 trials) and 8.4-13.0% for Tio R10 (2 trials).

CONCLUSIONS: Similar improvements in HRQoL were seen in COPD patients on maintenance therapy with tiotropium whether delivered via HandiHaler or Respimat. Treatment effects differed slightly between trials, possibly due to variations in study design.

CLINICAL IMPLICATIONS: Maintenance therapy with tiotropium delivered via HandiHaler or Respimat can significantly and consistently improve HRQoL in COPD patients.

DISCLOSURE: Donald Tashkin: Grant monies (from industry related sources): BI, Pearl, Sunovion, GSK , Consultant fee, speaker bureau, advisory committee, etc.: BI, AZ, Novartis, Pearl, Sunovion, Forest, Pfizer Paul Jones: Consultant fee, speaker bureau, advisory committee, etc.: BI Thomas Leonard: Employee: BI Dacheng Liu: Employee: BI Norbert Metzdorf: Employee: BI Valentina Zubek: Employee: BI Robert Wise: Grant monies (from industry related sources): GSK, BIPI, Merck, Pearl, Consultant fee, speaker bureau, advisory committee, etc.: GSK, BIPI, Mylan, Spiration, Sunovion, Pulmonx, Intermmune, Merck, Janssen, Medimmune, AZ, Novartis, Genentech

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543